AI-generated analysis. Always verify with the original filing.
Theravance Biopharma reported fourth quarter and full year 2025 financial results, including Q4 net income of $61.0 million, record YUPELRI profitability with $266.6 million full-year net sales triggering a $25 million milestone, and TRELEGY $3.9 billion sales triggering $50 million milestone. The company announced organizational restructuring for $60-70 million annualized cash flow savings starting Q3 2026 and accelerated strategic review including potential sale.
Event Type
Disclosure
Mandatory
Variant
8-K
and in Item 9.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 o
. Financial Statements and Exhibits. (d) Exhibits. 99.1 Press Release dated March 19, 2026 104 Cover Page Interactive Data File (cover page XBRL tags embedded w
| Metric | Value | Basis |
|---|---|---|
| Total Revenue | $45.90 | |
| Viatris Collaboration Revenue | $20.90 | |
| Research and Development Expenses | $7.40 | GAAP |
| Selling, General and Administrative Expenses | $18.50 | GAAP |
| Share-Based Compensation Expenses | $4.50 | |
| TRELEGY Milestone Income | $50.00 | |
| Income Tax Expense | $12.00 | GAAP |
| Net Income | $61.00 | GAAP |
| Non-GAAP Net Income from Operations | $3.10 | Non-GAAP |